Advertisement

PPARα, A Key Regulator of Hepatic Energy Homeostasis in Health and Disease

  • Nicolas Leuenberger
  • Walter WahliEmail author
Chapter

Abstract

Liver participates in the metabolism of almost all ­nutrients and contributes to maintaining balanced levels of energy-providing molecules in the circulating plasma. This homeostatic regulation plays a central role during the times of food deprivation, for instance, at night for animals feeding during the daytime, and when plenty of food has been ingested. For their contribution to the maintenance of this energy balance, liver cells depend on a variety of transcription factors that control gene expression. Among those, the peroxisome proliferator activated receptors (PPARs) and more particularly the PPARα isotype are the key actors in the regulation of hepatic functions. Below, we review the roles of PPARα in the liver, in both health and disease.

Keywords

Hepatic Stellate Cell Liver Fatty Acid Binding Protein Glycerol Kinase PPAR Ligand Fatty Acid Catabolism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The authors thank Dr. Liliane Michalik for discussions and stimulating comments on the manuscript. They also acknowledge grant support from the Swiss National Science Foundation and the Etat de Vaud.

References

  1. 1.
    Michalik L et al (2006) International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58(4):726–741CrossRefPubMedGoogle Scholar
  2. 2.
    Nuclear Receptors Nomenclature Committee (1999) A ­unified nomenclature system for the nuclear receptor ­superfamily. Cell 97(2):161–163CrossRefGoogle Scholar
  3. 3.
    Issemann I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347(6294):645–650CrossRefPubMedGoogle Scholar
  4. 4.
    Ashby J et al (1994) Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum Exp Toxicol 13(Suppl 2):S1–S117CrossRefGoogle Scholar
  5. 5.
    Forman BM, Chen J, Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 94(9):4312–4317CrossRefPubMedGoogle Scholar
  6. 6.
    Kliewer SA et al (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 94(9):4318–4323CrossRefPubMedGoogle Scholar
  7. 7.
    Krey G et al (1997) Fatty acids, eicosanoids, and ­hypolipidemic agents identified as ligands of peroxisome ­proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11(6):779–791CrossRefPubMedGoogle Scholar
  8. 8.
    Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270(22):12953–12956CrossRefPubMedGoogle Scholar
  9. 9.
    Schoonjans K et al (1995) Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem 270(33):19269–19276CrossRefPubMedGoogle Scholar
  10. 10.
    Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W (2006) From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45(2):120–159CrossRefPubMedGoogle Scholar
  11. 11.
    Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W (1993) Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci U S A 90(6):2160–2164CrossRefPubMedGoogle Scholar
  12. 12.
    Kliewer SA, Xu HE, Lambert MH, Willson TM (2001) Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res 56:239–263CrossRefPubMedGoogle Scholar
  13. 13.
    IJ A et al (2004) In vivo activation of PPAR target genes by RXR homodimers. EMBO J 23(10):2083–2091CrossRefGoogle Scholar
  14. 14.
    Mandard S, Muller M, Kersten S (2004) Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 61(4):393–416CrossRefPubMedGoogle Scholar
  15. 15.
    Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W (1992) Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68(5):879–887CrossRefPubMedGoogle Scholar
  16. 16.
    Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S (1992) The mouse peroxisome proliferator activated receptor recognizes a response element in the 5’ flanking sequence of the rat acyl CoA oxidase gene. EMBO J 11(2):433–439PubMedGoogle Scholar
  17. 17.
    Tien ES, Hannon DB, Thompson JT, Vanden Heuvel JP (2006) Examination of ligand-dependent coactivator recruitment by peroxisome proliferator-activated Receptor-alpha (PPARalpha). PPAR Res 2006:69612PubMedGoogle Scholar
  18. 18.
    Liu X et al (2008) The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 451(7180):846–850CrossRefPubMedGoogle Scholar
  19. 19.
    Gelman L, Michalik L, Desvergne B, Wahli W (2005) Kinase signaling cascades that modulate peroxisome proliferator-activated receptors. Curr Opin Cell Biol 17(2): 216–222CrossRefPubMedGoogle Scholar
  20. 20.
    Pascual G et al (2005) A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437(7059):759–763CrossRefPubMedGoogle Scholar
  21. 21.
    Hoekstra M, Kruijt JK, Van Eck M, Van Berkel TJ (2003) Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells. J Biol Chem 278(28):25448–25453CrossRefPubMedGoogle Scholar
  22. 22.
    Peters JM, Rusyn I, Rose ML, Gonzalez FJ, Thurman RG (2000) Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis 21(4): 823–826CrossRefPubMedGoogle Scholar
  23. 23.
    Bedu E, Wahli W, Desvergne B (2005) Peroxisome ­proliferator-activated receptor beta/delta as a therapeutic target for metabolic diseases. Expert Opin Ther Targets 9(4):861–873CrossRefPubMedGoogle Scholar
  24. 24.
    Hellemans K et al (2003) Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 124(1):184–201CrossRefPubMedGoogle Scholar
  25. 25.
    Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B (2001) Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142(10):4195–4202CrossRefPubMedGoogle Scholar
  26. 26.
    Anghel SI, Bedu E, Vivier CD, Descombes P, Desvergne B, Wahli W (2007) Adipose tissue integrity as a prerequisite for systemic energy balance: a critical role for peroxisome proliferator-activated receptor gamma. J Biol Chem 282(41): 29946–29957CrossRefPubMedGoogle Scholar
  27. 27.
    Patsouris D, Reddy JK, Muller M, Kersten S (2006) Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression. Endocrinology 147(3):1508–1516CrossRefPubMedGoogle Scholar
  28. 28.
    Remick J, Weintraub H, Setton R, Offenbacher J, Fisher E, Schwartzbard A (2008) Fibrate therapy: an update. Cardiol Rev 16(3):129–141CrossRefPubMedGoogle Scholar
  29. 29.
    Schoonjans K et al (1996) PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15(19): 5336–5348PubMedGoogle Scholar
  30. 30.
    Wang CS, McConathy WJ, Kloer HU, Alaupovic P (1985) Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 75(2):384–390CrossRefPubMedGoogle Scholar
  31. 31.
    Peters JM et al (1997) Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem 272(43):27307–27312CrossRefPubMedGoogle Scholar
  32. 32.
    Staels B et al (1995) Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 95(2): 705–712CrossRefPubMedGoogle Scholar
  33. 33.
    Vu-Dac N et al (2003) Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem 278(20):17982–17985CrossRefPubMedGoogle Scholar
  34. 34.
    Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N (1998) Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J Biol Chem 273(27):16710–16714CrossRefPubMedGoogle Scholar
  35. 35.
    Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J (1997) Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem 272(45):28210–28217CrossRefPubMedGoogle Scholar
  36. 36.
    Tan NS et al (2002) Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol 22(14): 5114–5127CrossRefPubMedGoogle Scholar
  37. 37.
    Schachtrup C, Emmler T, Bleck B, Sandqvist A, Spener F (2004) Functional analysis of peroxisome-proliferator-responsive element motifs in genes of fatty acid-binding proteins. Biochem J 382(Pt 1):239–245PubMedGoogle Scholar
  38. 38.
    Lefebvre P, Chinetti G, Fruchart JC, Staels B (2006) Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 116(3):571–580CrossRefPubMedGoogle Scholar
  39. 39.
    Brandt JM, Djouadi F, Kelly DP (1998) Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J Biol Chem 273(37): 23786–23792CrossRefPubMedGoogle Scholar
  40. 40.
    Barrero MJ, Camarero N, Marrero PF, Haro D (2003) Control of human carnitine palmitoyltransferase II gene transcription by peroxisome proliferator-activated receptor through a partially conserved peroxisome proliferator-responsive element. Biochem J 369(Pt 3):721–729CrossRefPubMedGoogle Scholar
  41. 41.
    Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103(11):1489–1498CrossRefPubMedGoogle Scholar
  42. 42.
    Patsouris D et al (2004) PPARalpha governs glycerol metabolism. J Clin Invest 114(1):94–103PubMedGoogle Scholar
  43. 43.
    Sugden MC, Bulmer K, Augustine D, Holness MJ (2001) Selective modification of pyruvate dehydrogenase kinase isoform expression in rat pancreatic islets elicited by starvation and activation of peroxisome proliferator-activated receptor-alpha: implications for glucose-stimulated insulin secre. Diabetes 50(12):2729–2736CrossRefPubMedGoogle Scholar
  44. 44.
    Koo SH et al (2004) PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat Med 10(5):530–534CrossRefPubMedGoogle Scholar
  45. 45.
    Du K, Herzig S, Kulkarni RN, Montminy M (2003) TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300(5625):1574–1577CrossRefPubMedGoogle Scholar
  46. 46.
    Kersten S et al (2001) The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism. FASEB J 15(11):1971–1978CrossRefPubMedGoogle Scholar
  47. 47.
    Cahill GF Jr (2006) Fuel metabolism in starvation. Annu Rev Nutr 26:1–22CrossRefPubMedGoogle Scholar
  48. 48.
    Hsu MH, Savas U, Griffin KJ, Johnson EF (2001) Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells. J Biol Chem 276(30): 27950–27958CrossRefPubMedGoogle Scholar
  49. 49.
    Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5(6):426–437CrossRefPubMedGoogle Scholar
  50. 50.
    Inagaki T et al (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5(6):415–425CrossRefPubMedGoogle Scholar
  51. 51.
    Staels B (2006) When the Clock stops ticking, metabolic syndrome explodes. Nat Med 12(1):54–55; discussion 55CrossRefPubMedGoogle Scholar
  52. 52.
    Yang X et al (2006) Nuclear receptor expression links the circadian clock to metabolism. Cell 126(4):801–810CrossRefPubMedGoogle Scholar
  53. 53.
    Lemberger T et al (1996) Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. J Biol Chem 271(3):1764–1769CrossRefPubMedGoogle Scholar
  54. 54.
    Isobe Y, Isobe M (1998) Circadian rhythm of Arg-vasopressin contents in the suprachiasmatic nucleus in relation to corticosterone. Brain Res 800(1):78–85CrossRefPubMedGoogle Scholar
  55. 55.
    Panda S et al (2002) Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 109(3): 307–320CrossRefPubMedGoogle Scholar
  56. 56.
    Rudic RD et al (2004) BMAL1 and CLOCK, two essential components of the circadian clock, are involved in glucose homeostasis. PLoS Biol 2(11):e377CrossRefGoogle Scholar
  57. 57.
    Turek FW et al (2005) Obesity and metabolic syndrome in circadian Clock mutant mice. Science 308(5724): 1043–1045CrossRefPubMedGoogle Scholar
  58. 58.
    Lemmer B (2006) Clinical chronopharmacology of the cardiovascular system: hypertension and coronary heart disease. Clin Ter 157(1):41–52PubMedGoogle Scholar
  59. 59.
    Lemmer B (2006) The importance of circadian rhythms on drug response in hypertension and coronary heart disease – from mice and man. Pharmacol Ther 111(3):629–651CrossRefPubMedGoogle Scholar
  60. 60.
    Desvergne B, Michalik L, Wahli W (2004) Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 18(6):1321–1332CrossRefPubMedGoogle Scholar
  61. 61.
    Evans RM, Barish GD, Wang YX (2004) PPARs and the complex journey to obesity. Nat Med 10(4):355–361CrossRefPubMedGoogle Scholar
  62. 62.
    Semple RK, Chatterjee VK, O’Rahilly S (2006) PPAR gamma and human metabolic disease. J Clin Invest 116(3):581–589CrossRefPubMedGoogle Scholar
  63. 63.
    Devchand PR (2008) Glitazones and the cardiovascular system. Curr Opin Endocrinol Diabetes Obes 15(2):188–192PubMedGoogle Scholar
  64. 64.
    Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W (1996) The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384(6604):39–43CrossRefPubMedGoogle Scholar
  65. 65.
    Zandbergen F, Plutzky J (2007) PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta 1771(8): 972–982PubMedGoogle Scholar
  66. 66.
    Gervois P et al (2001) Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. J Biol Chem 276(36): 33471–33477CrossRefPubMedGoogle Scholar
  67. 67.
    Kleemann R et al (2004) Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 103(11):4188–4194CrossRefPubMedGoogle Scholar
  68. 68.
    Peters JM, Cheung C, Gonzalez FJ (2005) Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand? J Mol Med 83(10):774–785CrossRefPubMedGoogle Scholar
  69. 69.
    Peters JM, Cattley RC, Gonzalez FJ (1997) Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14, 643. Carcinogenesis 18(11):2029–2033CrossRefPubMedGoogle Scholar
  70. 70.
    Rao MS, Reddy JK (1996) Hepatocarcinogenesis of peroxisome proliferators. Ann N Y Acad Sci 804:573–587CrossRefPubMedGoogle Scholar
  71. 71.
    Yeldandi AV, Rao MS, Reddy JK (2000) Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis. Mutat Res 448(2):159–177PubMedGoogle Scholar
  72. 72.
    Shah YM, Morimura K, Yang Q, Tanabe T, Takagi M, Gonzalez FJ (2007) Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol 27(12):4238–4247CrossRefPubMedGoogle Scholar
  73. 73.
    Johnson SM et al (2005) RAS is regulated by the let-7 microRNA family. Cell 120(5):635–647CrossRefPubMedGoogle Scholar
  74. 74.
    He L et al (2005) A microRNA polycistron as a potential human oncogene. Nature 435(7043):828–833CrossRefPubMedGoogle Scholar
  75. 75.
    Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, Aoyama T (2008) PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest 118(2):683–694PubMedGoogle Scholar
  76. 76.
    Kiyosawa K et al (2004) Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 127(5 Suppl 1): S17–S26CrossRefGoogle Scholar
  77. 77.
    Moriya K et al (1997) Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78(7): 1527–1531PubMedGoogle Scholar
  78. 78.
    Michalik L, Wahli W (2008) PPARs mediate lipid signaling in inflammation and cancer. PPAR Res. 2008:134059Google Scholar
  79. 79.
    Panigrahy D et al (2008) PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A 105(3): 985–990CrossRefPubMedGoogle Scholar
  80. 80.
    Elsharkawy AM, Oakley F, Mann DA (2005) The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 10(5):927–939CrossRefPubMedGoogle Scholar
  81. 81.
    Michalik L, Wahli W (2006) Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest 116(3):598–606CrossRefPubMedGoogle Scholar
  82. 82.
    Ip E, Farrell G, Hall P, Robertson G, Leclercq I (2004) Administration of the potent PPARalpha agonist, Wy-14, 643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 39(5):1286–1296CrossRefPubMedGoogle Scholar
  83. 83.
    Toyama T et al (2004) PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem Biophys Res Commun 324(2):697–704CrossRefPubMedGoogle Scholar
  84. 84.
    Skrtic S et al (2005) Decreased expression of peroxisome proliferator-activated receptor alpha and liver fatty acid binding protein after partial hepatectomy of rats and mice. Liver Int 25(1):33–40CrossRefPubMedGoogle Scholar
  85. 85.
    Anderson SP, Yoon L, Richard EB, Dunn CS, Cattley RC, Corton JC (2002) Delayed liver regeneration in peroxisome proliferator-activated receptor-alpha-null mice. Hepatology 36(3):544–554CrossRefPubMedGoogle Scholar
  86. 86.
    Wheeler MD, Smutney OM, Check JF, Rusyn I, Schulte-Hermann R, Thurman RG (2003) Impaired Ras membrane association and activation in PPARalpha knockout mice after partial hepatectomy. Am J Physiol Gastrointest Liver Physiol 284(2):G302–G312Google Scholar
  87. 87.
    Hazra S et al (2004) Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 279(12): 11392–11401CrossRefPubMedGoogle Scholar
  88. 88.
    Yavrom S, Chen L, Xiong S, Wang J, Rippe RA, Tsukamoto H (2005) Peroxisome proliferator-activated receptor gamma suppresses proximal alpha1(I) collagen promoter via inhibition of p300-facilitated NF-I binding to DNA in hepatic stellate cells. J Biol Chem 280(49):40650–40659CrossRefPubMedGoogle Scholar
  89. 89.
    Marchesini G et al (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37(4): 917–923CrossRefPubMedGoogle Scholar
  90. 90.
    Day CP, James OF (1998) Steatohepatitis: a tale of two “hits”? Gastroenterology 114(4):842–845CrossRefPubMedGoogle Scholar
  91. 91.
    Belfort R et al (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355(22):2297–2307CrossRefPubMedGoogle Scholar
  92. 92.
    Kallwitz ER, McLachlan A, Cotler SJ (2008) Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol 14(1):22–28CrossRefPubMedGoogle Scholar
  93. 93.
    Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B (2007) Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 1771(8): 1065–1081PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Center for Integrative Genomics, National Research Center Frontiers in GeneticsUniversity of LausanneLausanneSwitzerland

Personalised recommendations